1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
(
- Contribution to journal › Article
-
Mark
Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy
(
- Contribution to journal › Article
- 2021
-
Mark
Clinical and genomic characterization of patients diagnosed with the provisional entity Acute myeloid leukemia with BCR-ABL1, a Swedish population-based study
(
- Contribution to journal › Article
- 2020
-
Mark
Cell Surface Markers as Therapeutic Targets in Myeloid Leukemia
2020) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article
-
Mark
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
(
- Contribution to journal › Article
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
- 2017
-
Mark
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells
(
- Contribution to journal › Article
-
Mark
Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib
(
- Contribution to journal › Article